Ten Years of Adjuvant Tamoxifen Found Superior to Five
December 6, 2012|Hematology and Oncology
Author and Disclosure Information
AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM
"I think that the amount of benefit they’ll get in continuing will be small enough that that would be a perfectly rational decision. An additional one-third reduction in a very small risk is still a very small benefit," Dr. Ravdin observed.
Simultaneous with Prof. Gray’s presentation in San Antonio, the ATLAS results were published online (Lancet 2012 Dec. 5 [doi: 10.1016/S0140-6736(12)61963-1]).
The ATLAS trial was funded by Cancer Research UK, the UK Medical Research Council, AstraZeneca, the U.S. Army, and EU Biomed. Dr. Gray reported having no financial conflicts.
